03.08.21 -- Appili's CRO Selection Reflects Realities Of Clinical Studies In A Pandemic
03.08.21 -- Appili's CRO Selection Reflects Realities Of Clinical Studies In A Pandemic Orphan drugs are notorious for their high costs and risk factors, which are attributed to smaller patient pools and higher development and launch costs. Attend this webinar to learn more about key trends that are causing the rise of orphan drug indications, fast-tracking early development phases that will lead to commercial success, and more! By Ed Miseta, chief editor, Clinical Leader When Appili Therapeutics was ready to enter a Phase 3 trial for a COVID-19 t...
Source: clinicalleader.com